Using the same approach outlined in Supplementary Figure S1 to examine the effect of the PNPLA3 GG variant on MASLD disease progression, we next used both the PNPLA3 GG variant and CC wild-type LAMPS to evaluate the efficacy of resmetirom (RezdiffraTM), a thyroid hormone receptor beta (THR-β) agonist recently approved for the treatment of MASLD (Harrison et al., 2024; Harrison et al., 2019; Harrison et al., 2023). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.